PRQR
PRQR
NASDAQ · Biotechnology

Proqr Therapeutics Nv

$1.50
+0.04 (+2.74%)
As of Feb 8, 2:07 PM ET ·
Analyst Consensus
Strong Buy
15
Analysts
High
Coverage
Buy 14 93%
Hold 1 7%
Sell 0 0%
Price Target
Analyst Price Target +513.3% upside
Low Target $6.27
Average Target $9.20
High Target $10.38
Current Price $1.50
Current
$1.50
Target
$9.20
$6.27 $9.20 avg $10.38
Scenario Analysis
Bear Case
$6.27
318.0%
Low target
Base Case
$9.20
+513.3%
Avg target
Bull Case
$10.38
+592.0%
High target
Risk/Reward
1.9x
Balanced
Price in Context
52-Week High
$9.88
-84.8% from high
52-Week Low
$4.56
+-67.1% from low
Target vs 52W High
$9.20
-6.9% vs high
Next Earnings Report
Feb 19, 2026 · After Market Close
3d
until earnings
EPS Est: $-0.10
Earnings in 3 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 37 68% $257.58 +15.3%
AMGN
Amgen Inc
Hold 41 54% $190.87 -50.3%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +137.8%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 77% $438.34 -8.3%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.2%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -68.8%
INSM
Insmed Inc
Strong Buy 27 93% $143.40 -4.3%
BIIB
Biogen Inc
Hold 42 48% $91.45 -54.5%